Edible Ginger derived Nano lipids Loaded with Doxorubicin as a Novel Drug delivery Approach for Colon Cancer Therapy.
The use of nanotechnology for drug delivery has shown great promise for improving cancer treatment. However, potential toxicity, hazardous environmental effects, issues with large scale production, and potential excessive costs are challenges that confront their further clinical applications. Here, we describe a nanovector made from ginger derived lipids that can serve as a delivery platform for the therapeutic agent doxorubicin (Dox) to treat colon cancer. We created nanoparticles from ginger and reassembled their lipids into ginger derived nanovectors (GDNVs) A subsequent characterization showed that GDNVs were efficiently taken up by colon cancer cells. Viability and apoptosis assays and electric cell substrate impedance sensing technology revealed that GDNVs exhibited excellent biocompatibility up to 200 mmol/l; by contrast, cationic liposomes at the same concentrations decreased cell proliferation and increased apoptosis. GDNVs were capable of loading Dox with high efficiency and showed a better pH dependent drug release profile than commercially available liposomal Dox. Modified GDNVs conjugated with the targeting ligand folic acid mediated targeted delivery of Dox to Colon 26 tumors in vivo and enhanced the chemotherapeutic inhibition of tumor growth compared with free drug. Current experiments explore the feasibility of producing nature derived nanoparticles that are effective as a treatment vehicle while potentially attenuating the issues related to traditional synthetic nanoparticles.
Molecular therapy the journal of the American Society of Gene Therapy